Edition:
United Kingdom

Mallinckrodt Plc (MNK.N)

MNK.N on New York Stock Exchange

20.63USD
18 Jan 2019
Change (% chg)

$0.73 (+3.67%)
Prev Close
$19.90
Open
$19.93
Day's High
$20.65
Day's Low
$19.75
Volume
267,781
Avg. Vol
522,943
52-wk High
$36.63
52-wk Low
$11.66

Select another date:

Wed, Dec 12 2018

FDA declines to approve Mallinckrodt's abuse-deterrent opioid painkiller

The U.S. Food and Drug Administration has declined to approve an abuse-deterrent version of Mallinckrodt Plc's opioid painkiller Roxicodone, saying some parts of the company's application need further evaluation.

UPDATE 1-FDA declines to approve Mallinckrodt's abuse-deterrent opioid painkiller

Dec 12 The U.S. Food and Drug Administration has declined to approve an abuse-deterrent version of Mallinckrodt Plc's opioid painkiller Roxicodone, saying some parts of the company's application need further evaluation.

FDA declines to approve reformulated Mallinckrodt opioid

Dec 12 Mallinckrodt Plc said on Wednesday the U.S. Food and Drug Administration declined to approve an abuse-deterrent version of its opioid painkiller Roxicodone.

Mallinckrodt to spin off generics business, but to keep options open

Mallinckrodt Plc plans to spin off its specialty generics business to shareholders by the second half of 2019, but said it was still open to a sale of the unit.

UPDATE 3-Mallinckrodt to spin off generics business, but to keep options open

* Branded drug co will rely on Acthar for nearly 50 pct of sales

Mallinckrodt plans to spin off specialty generics business

Dec 6 Drugmaker Mallinckrodt Plc said on Thursday it planned to spin off its specialty generics business to shareholders by the second half of 2019.

Select another date: